RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein^®, has raised 210 million JPY (US$1.4M) in Series A extension funding.

This funding will advance RevolKa’s drug discovery programs for rare diseases  and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC (Tomoya Nagata, Managing Partner, CEO) and TOHOKU University Venture Partners Co., Ltd. (Tetsuro Higuchi, President & CEO) with participation from DEEPCORE Inc. (Katsumasa Niki, President & CEO).

RevolKa’s core technology, aiProtein^® is a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many successful outcomes in collaboration with partner companies.